Retargeted Clostridial Neurotoxins as Novel Agents for Treating Chronic Diseases
Open Access
- 7 November 2011
- journal article
- research article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 50 (48) , 10419-10421
Abstract
Botulinum neurotoxin (BoNT) A and B are used to treat neuropathic disorders; if retargeted, these agents could be used to treat medical conditions that involve secretion from nonneuronal cells. Here, we report novel strategies for successfully retargeting BoNTs, and also tetanus neurotoxin (TeNT), to primary human blood monocyte-derived macrophages where BoNT/B inhibited the release of tumor necrosis factor-α, a cytokine that plays a key role in inflammation. Furthermore, mice treated with retargeted BoNT/B exhibited a significant reduction in macrophage (MΦ) recruitment, indicating that these toxins can be used to treat chronic inflammation.Keywords
This publication has 20 references indexed in Scilit:
- SV2 Mediates Entry of Tetanus Neurotoxin into Central NeuronsPLOS Pathogens, 2010
- Cell entry strategy of clostridial neurotoxinsJournal of Neurochemistry, 2009
- How Does Synaptotagmin Trigger Neurotransmitter Release?Annual Review of Biochemistry, 2008
- Cytokines and atherosclerosis: a comprehensive review of studies in miceCardiovascular Research, 2008
- SNAREing immunity: the role of SNAREs in the immune systemNature Reviews Immunology, 2006
- The structure and mode of action of different botulinum toxinsEuropean Journal of Neurology, 2006
- TNF-α as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritisClinical Science, 2005
- Botulinum toxin in clinical practiceJournal of Neurology, Neurosurgery & Psychiatry, 2004
- A Conjugate Composed of Nerve Growth Factor Coupled to a Non-toxic Derivative ofClostridium botulinumNeurotoxin Type A can Inhibit Neurotransmitter Releasein VitroGrowth Factors, 2000
- VAMP/synaptobrevin isoforms 1 and 2 are widely and differentially expressed in nonneuronal tissues.Journal of Cell Biology, 1996